Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists—a nationwide population-based cohort study based on 2010–2013 French Health Insurance data-Reference-Cited by-同舟云学术

Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists—a nationwide population-based cohort study based on 2010–2013 French Health Insurance data

Published:2017-05 Issue: Volume:77 Page:99-108
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Scailteux Lucie-Marie,Vincendeau Sébastien,Balusson Frédéric,Leclercq Christophe,Happe André,Le Nautout Béranger,Polard Elisabeth,Nowak Emmanuel,Oger Emmanuel

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference32 articles.

1. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer;Heidenreich;Eur Urol,2014

2. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials;Nguyen;JAMA,2011

3. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies;Byar;NCI Monogr Publ Natl Cancer Inst,1988

4. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer;Keating;J Clin Oncol,2006

5. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies;Zhao;PloS One,2014

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular and Thromboembolic Events in Patients With Localized Prostate Cancer Receiving Intensified Neoadjuvant Androgen Deprivation: A Systematic Review and Meta-Analysis;Clinical Genitourinary Cancer;2024-06

2. A Model‐Informed Drug Development Approach to Design a Phase 3 Trial of Teverelix Drug Product in Advanced Prostate Cancer Patients with Increased Cardiovascular Risk;Clinical Pharmacology in Drug Development;2024-05-17

3. Perspectives on the Cardiovascular and Metabolic Effects of Androgen Deprivation Therapy in Prostate Cancer;Current Oncology Reports;2024-02-20

4. Efficacy, tolerability, and safety of teverelix DP in patients with advanced prostate cancer: A multicenter, open‐label, phase 2 trial;The Prostate;2024-02-04

5. Sex differences in the cardiovascular effects of GnRH analogues;Journal of Endocrinology;2024-01-24